Skip to content
Review

Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections

Jul 2026 · Drugs · Vol 86, pp. 1421 - 1434 · 0 citations · 103 references
Medicine

TL;DR

A narrative review, including the pharmacological characteristics of dalbavancin (DAL) and oritavancin (ORI), the only currently available laLGPs, as well as their approved and “off-label” use reported in the literature to date.

View source

Similar papers

Review Open access Aug 2026

Clinical Evidence in Respiratory and Urinary Tract Infections: Focus on Ceftibuten

Abstract Background Antimicrobial resistance (AMR) is one of the most pressing global health problems, resulting from the misuse and overuse of antibiotics across various sectors, which has led to the emergence and spread of resistant microorganisms. AMR occurs when microorganisms no longer respond to antibiotics. In I...

Gabriele Cortellini, M. Del Re, E. Ponticiello et al. · 0 citations
Review

QUALITY IN

Aleksandra Obszańska · 0 citations
Open access Sep 2026

The Direct and Potentiating Antimicrobial Activities of Zafirlukast

Background: Antimicrobial resistance is at alarming levels. Methicillin-resistant Staphylococcus aureus is a clinical concern and has been classified as one of the so-called ESKAPE pathogens. The increase in resistance coupled with the lack of new agents in development requires innovative ways of developing new antimic...

Ed Siegwart, Ajay Mistry, John George · 0 citations
Review Open access Sep 2026

Revisiting the mode of action of daptomycin considering the inoculum effect and a novel liposome-MIC-competition assay.

Daptomycin (DAP) is a cyclic lipopeptide drug for intravenous application against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In spite of numerous studies, its mode of action remains controversial. This is partially due to the fact that no attention has been paid to the strong dep...

Sarah Crocoll, L. Forssmann, Luisa Munz et al. · 0 citations
Sep 2026

Engineering lipopeptide-gramicidin S conjugates to combat multidrug-resistant Acinetobacter baumannii and other ESKAPE pathogens.

Novel Gramicidin S analogues demonstrated broad-spectrum antibacterial activity against WHO priority pathogens, thus highlighting their potential as promising candidates for further therapeutic development.

Harshita Dubkara, Swechchha Singh, Rahul Maitra et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.